Our view following announcement of potential spinoff.

We welcome the CEO change at CSL but relatively soft plasma performance will postpone recovery

Higher sales and a new loan facility increase our conviction.

Despite a surging share price a weakening competitive position causes a reassessment of our view.

Our analysts believe a long-term margin recovery is underway.

Investors are ignoring a strong long-term outlook.

Shares plunge after guidance is cut.

Sales growth at CSL was lower than expected but streamlining the business has its perks.

Cochlear’s met expectations, but investors overly optimistic.

Margins improve but primary market is limited.